American Heart Journal
Volume 144, Issue 5 , Pages 769-781, November 2002

Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management☆☆☆★★★

Nashville, Tenn, and Durham, NC

From the aVanderbilt University Medical Center, Nashville, Tenn, and the bDuke Clinical Research Institute, Durham, NC

Abstract 

Am Heart J 2002;144:769-81.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Supported by unrestricted educational grants from: AstraZeneca Pharmaceuticals, Bayer Corporation, Hoffman-La Roche, Inc, ICAgen, Inc, Eli Lilly & Company, Pfizer, Inc, Pharmacia Corporation, Almirall Prodesfarma, Schering-Plough Research Institute, Bristol-Myers Squibb Company

☆☆ *Participants in the meeting are listed in the Appendix to this article.

★ Reprint requests: Mark E. Anderson, MD, PhD, Vanderbilt University Medical Center, 315 Preston Research Building, Nashville, TN 37232-6300.

★★ E-mail: mark.anderson@mcmail.vanderbilt.edu

PII: S0002-8703(02)00184-9

doi:10.1067/mhj.2002.125804

American Heart Journal
Volume 144, Issue 5 , Pages 769-781, November 2002

Article Tools

* Image Usage & Resolution